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Evidence on the relationship between genetics and mental health are flourishing. However, few 
studies are evaluating early biomarkers that might link genes, environment, and psychopathology. We 
aimed to study telomere length (TL) and epigenetic age acceleration (AA) in a cohort of adolescents 
with and without anxiety disorders (N = 234). We evaluated a representative subsample of participants 
at baseline and after 5 years (n = 76) and categorized them according to their anxiety disorder 
diagnosis at both time points: (1) control group (no anxiety disorder, n = 18), (2) variable group 
(anxiety disorder in one evaluation, n = 38), and (3) persistent group (anxiety disorder at both time 
points, n = 20). We assessed relative mean TL by real‑time quantitative PCR and DNA methylation 
by Infinium HumanMethylation450 BeadChip. We calculated AA using the Horvath age estimation 
algorithm and analyzed differences among groups using generalized linear mixed models. The 
persistent group of anxiety disorder did not change TL over time (p = 0.495). The variable group had 
higher baseline TL (p = 0.003) but no accelerated TL erosion in comparison to the non‑anxiety control 
group (p = 0.053). Furthermore, there were no differences in AA among groups over time. Our findings 
suggest that adolescents with chronic anxiety did not change telomere length over time, which could 
be related to a delay in neuronal development in this period of life.
Anxiety disorders are characterized by maladaptive responses to threats and are considered one of the largest 
group of disabling mental disorders in childhood and  adolescence1. The estimated lifetime prevalence of anxi-
ety disorders in studies with children or adolescents is about 15–20%2 and is associated with a considerable 
degree of fluctuation in diagnostic status over  time3,4. The persistence of anxiety symptoms and the chronicity 
of anxiety disorders are common, with recurrence of the same or different diagnoses across several time points 
throughout  life5–7.
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From a physiological perspective, anxiety disorders are stressful conditions, normally accompanied by deregu-
lation of stress systems such as the hypothalamic–pituitary–adrenal axis, the autonomic nervous system, and the 
immune  system8,9. The presence of different stressful conditions has been associated with accelerated  aging10–12 
evaluated through telomere length (TL) shortening and epigenetic age acceleration (AA) from DNA methylation 
(DNAm) profiles of cytosine phosphate guanines (CpGs). These measurements can be used as markers of cellular 
age according to different  studies12–15. Despite the association between stress, immune system and anxiety, and 
between stress and age acceleration, few studies have addressed TL and AA as biomarkers in anxiety disorders.
TL is considered a “biological clock” but the literature has shown conflicting results when evaluating the rela-
tionship between leukocyte TL as a biological aging marker and psychiatric  disorders16. Some studies reported 
that TL is associated with the vulnerability to anxiety  disorders17–19, however other prospective studies evaluat-
ing if anxiety precedes telomere shortening showed inconsistent  findings20–23. Two recent meta-analyses have 
shown small (− 0.06)24 to moderate effect sizes (− 0.53)16 in telomere shortening in adult patients with an anxiety 
disorder.
The recent literature has suggested AA as an estimate of the discrepancy between DNAm age and chronologi-
cal age, measurable by residual from a regression model of DNAm age against chronological  age14,25–28. Some 
studies investigated the association between DNAm age with posttraumatic stress  disorder29,30,  schizophrenia31,32, 
 depression33, generalized anxiety  disorder29 and bipolar  disorder26, and also found inconsistent findings. In 
adolescence, AA was associated with inflammation, the probability of middle age cardiovascular  disease34, as 
well as higher odds for internalizing and thought  problems35.
Although markers of cellular aging have been studied in psychiatric  disorders16,33,36,37, there are few studies 
evaluating this association in  youth23,35. Therefore, it is important to understand if a prevalent and early onset 
disorder such as anxiety disorder could accelerate aging at the molecular level and what would be the implica-
tions for neuronal development in this sensitive phase. Thus, to investigate if anxiety disorder would modify the 
cellular aging markers in adolescents, we longitudinally evaluated the association between TL, AA, and anxiety 
disorders over 5 years in this age group.
Results
Baseline characteristics. The sample re-evaluated after 5 years (n = 76) was representative of the whole 
234 non-medicated children and adolescents recruited from public schools at baseline as described  elsewhere38. 
Similarly, the sub-sample we used to evaluate the epigenetic data did not differ from the whole sample accord-
ing to Bortoluzzi et al.39. Descriptive data about the baseline sample and the 5-year follow-up one is depicted 
in Table 1. The mean age of the total sample at baseline was 13 years of age, 61% was female and most of the 
participants have Caucasian ancestry.
TL and AA within and between the two time points. We considered as outcomes, in our analyses, 
the telomere length (TL) and the epigenetic age acceleration (AA) defined as the residuals from regressing DNA 
methylation (DNAm) age on chronological age. We assessed the mean between-group differences at each time 
point and within-group differences (and for the overall sample) across the time points (Table 1). The TL of the 
variable group was significantly higher as compared with the control and with the persistent group at baseline 
Table 1.  Descriptive data on adolescent anxiety diagnostic evaluated in baseline and follow-up. Chi-
squared test was applied for testing sex and race/ethnicity between anxiety groups. Analysis of variance and 
Tukey post-hoc tests were used to examine telomere length, epigenetic age acceleration and chronological 
age differences among anxiety groups within each year and for overall sample between years (a). *p < 0.05 
compared with all other anxiety groups within the same time point (Tukey post-hoc test); **p < 0.05 compared 










(n = 18) Variable (n = 38) Persistent (n = 20)
Total sampleª 
(N = 76)
Telomere length (base pairs)
Mean (SD) 1.22 (0.566) 2.20 (1.47)* 1.25 (0.826) 1.70 (1.23) 0.759 (0.359)** 0.853 (0.628)** 1.13 (0.528) 0.891 (0.553)**
Epigenetic age acceleration (years)
Mean (SD) − 1.45 (7.98) 0.119 (8.07) − 3.03 (3.86) − 1.14 (7.21) 2.05 (4.14) 0.582 (3.82) 1.86 (4.51)** 1.33 (4.06)**
Age (years)
Mean (SD) 13.2 (2.42) 13.8 (2.48) 12.5 (1.95) 13.4 (2.37) 17.2 (2.50)** 17.7 (2.58)** 16.3 (2.08)** 17.2 (2.48)**
Sex
Female 9 (50%) 22 (58%) 15 (75%) 46 (61%)
Male 9 (50%) 16 (42%) 5 (25%) 30 (39%)
Race/ethnicity
Caucasian 10 (56%) 25 (66%) 13 (65%) 48 (63%)
African Brazilian 2 (11%) 5 (13%) 4 (20%) 11 (14%)
Mixed 5 (28%) 8 (21%) 3 (15%) 16 (21%)
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 (F(2,47) = 4.212, p = 0.021). At the second evaluation, there were no TL differences between the anxiety groups. 
There were no differences in AA among the groups at both evaluations. Cellular aging markers have different 
mean levels from baseline to follow-up within each anxiety group and in the overall sample. The TL of the vari-
able group decreased from the first to the second assessment  (t(36) = 4.10, p = 3.16 ×  10–3), which was not observed 
for AA  (t(34) =  − 0.237, p = 0.818). The same effect was observed for the persistent group regarding TL  (t(16) = 2.45, 
p = 0.025), and AA  (t(16) =  − 1.454, p = 0.162). However, the TL of the persistent group did not change over time 
 (t(18) = 0.467, p = 0.645), whereas AA increased  (t(18) =  − 2.728, p = 0.013). The TL of the overall sample decreased 
from the first to the second assessment  (t(74) = 4.21, p = 8.13 ×  10–5) and AA increased  (t(74) =  − 2.009, p = 0.048). 
Data are shown in Table 1 using ANOVA and Tuckey post-hoc tests for between-group comparisons and t test 
for within-group comparisons.
We also analyzed possible correlations between TL and AA at baseline and follow-up using Spearman cor-
relations and found that TL did not correlate with AA either at baseline (r = 0.194; p = 0.305) or at follow-up 
(r = 0.182; p = 0.287). The correlation of chronological age with TL (r = − 0.302, p = 0.002) and with DNAm age 
(r = 0.283, p = 0.007) were significant. Nonetheless, the correlation between AA with chronological age was not 
significant (r = -0.015; p = 0.903).
TL and AA changes across anxiety disorder groups over time. We conducted a generalized lin-
ear mixed models (GLMM) analysis to examine whether TL and AA changed across anxiety disorder groups. 
Considering the TL, our data suggested no significant difference in the persistent group compared to control 
(p = 0.834 in the adjusted model) at baseline. However, we found a significant difference in the variable group, 
which had higher baseline TL in comparison to the control group (T/S ratio = 0.989; 95% CI 0.384, 1.594; 
p = 0.003 in the adjusted model, Fig. 1; Table S1). Furthermore, considering TL changes over time, we also found 
that the persistent group did not change its TL over time (p = 0.495 for the group by time interaction in the 
adjusted model). Moreover, we demonstrated that the variable group had higher TL erosion rate in comparison 
to control (T/S ratio = − 0.894; 95% CI − 1.711, − 0.076; p = 0.038), nevertheless when we adjusted the model 
for age, sex and ethnicity, this difference was no longer significant (T/S ratio = − 0.864; 95% CI − 1.696, − 0.031; 
p = 0.053, Fig. 1; Table S1). There were no significant differences among the groups regarding the AA (Fig. 2; 
Table S2).
We decomposed the variable group into the incident and the remittent anxiety courses and run the same set 
of analysis as a sensitivity analysis (see “Supplementary information”). Descriptive data of these groups can be 
found in Table S3. Results of the GLMM analysis demonstrated that both the incident and the remittent groups 
have the same associations with higher TL as reported by the variable group and no association with AA when 
compared to controls, revealing the consistency of combining incident and remittent anxiety courses into one 
group only (Figures S1, S2; Tables S4, S5). We also performed two supplementary linear regression models to 
predict TL and AA changes over time (deltas) by baseline anxiety diagnostic status to further understand the 
association of anxiety with cellular aging markers without considering data structure and anxiety courses. Con-
sidering the linear model, we found no association of anxiety diagnostic status versus no diagnosis at baseline 
with TL and AA changes (see “Supplementary information”).
Figure 1.  Unadjusted (A) and adjusted (B) interaction of anxiety diagnostic course (colored lines with shaded 
95% CI) on telomere length change (y-axis) between baseline and follow-up five years later (x-axis).
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Discussion
In this study, we aimed to investigate how cell aging markers could be associated with anxiety disorder over time 
in a sample of adolescents. For this propose, we investigated relative TL shortening and AA as markers of cellular 
aging, in a community sample of adolescents in two different evaluations, at baseline and after 5 years. Differ-
ent from our a priori hypothesis, the persistent group of anxiety disorder had neither shortened TL nor higher 
AA in comparison to controls. Instead, this group interestingly did not change telomere length over time. On 
the other hand, the variable group had higher baseline TL but no accelerated TL erosion in comparison to the 
control group, after adjusting for age, sex and ethnicity. These findings suggest that although the general trend 
was TL shortening over time, individuals with persistent chronic anxiety disorders did not follow the trend of 
shortening the TL.
TL generally decreases progressively over the lifespan. In early life stages, telomeres undergo shortening at an 
accelerated rate of approximately 170–270 bp per year, which is gradually reduced until reaching a  plateau40,41, 
ranging between 32.2 and 45.5 bp per year in adult  studies36,42. In this sense, we hypothesized if the lack of TL 
shortening found in the persistent group could be associated with a delay in brain maturation in chronic anxious 
adolescents. Some studies suggested that elevated anxiety and depression might be characterized by a delayed 
maturation of the ventromedial prefrontal cortex and an altered trajectory of cortical  thinning43,44. Similarly, 
there has been debate as to whether attention-deficit hyperactivity disorder (ADHD) is a consequence partly of 
delay in brain maturation, particularly in prefrontal regions related to attention and motor  planning45.
On the other hand, a variable or non-persistent course of anxiety disorders seems to be less deleterious than a 
persistent course. A recent multigenerational study showed clinically relevant differences among children with-
out anxiety or with low anxiety, non-persistent anxiety, and persistent anxiety in both  generations46. Therefore 
individuals with remittent or incident (variable) anxiety course seem to be different from those with a chronic 
anxiety disorder. It is important to note that higher severity of symptoms and clinical severity indicators have 
been associated with higher persistence of anxiety  disorders5,6,47. Thus, we can suggest that adolescents with 
a non-persistent (variable) course of anxiety disorders would have less severe symptoms and that they have a 
developmental trajectory closer to those from the typical developmental course. In agreement, Newman et al.43 
hypothesized that, in children with higher generalized anxiety, an increase in VMPFC “territory” may be some-
what delayed as compared to those without anxiety.
Telomere length and telomerase activity seem to modulate neuronal differentiation since telomerase expres-
sion and activity is downregulated during neuronal  differentiation48 and its overexpression appears to inhibit 
differentiation in neural cell  lines49. Decline in telomerase activity during brain development signals cells to exit 
the cell cycle and to differentiate into neurons or glial  cells50. Consistently, a study with rodents showed a marked 
decrease in telomerase activity throughout the mice brain during the early period of  development51, and a recent 
study found increased TL associated to decreased brain weights, increased anxiety‐like behavior, altered pain 
response, and increased levels of inflammation in early life stress in adolescent  rodents52.
As no participants from our sample were using psychiatric medication, our findings concerning no TL short-
ening in persistent anxiety could not be due to the use of pharmacotherapy with protective effect or elongation 
inducer of telomeres, such as  lithium53. Nevertheless, we found a significantly higher TL baseline evaluation 
in the variable group, similar to the findings of the incident and remittent groups evaluated separately, even in 
age, gender, and ethnicity-controlled analyses. This could be due to genetic factors since TL had an estimated 
heritability of 0.7054.
Figure 2.  Unadjusted (A) and adjusted (B) interaction of anxiety diagnostic course (colored lines with shaded 
95% CI) on epigenetic age acceleration change (y-axis) between baseline and follow-up five years later (x-axis).
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Very few longitudinal studies have examined the association between anxiety disorder and TL. TL was shorter 
in individuals with remitted and current depressive and/or anxiety disorder (n = 2,292) as compared to healthy 
control subjects (n = 644) in a large longitudinal  study21. However, these authors found no difference in telomere 
attrition rate among the groups when they evaluated TL and diagnosis status over time (from baseline to 6-year 
follow-up). Prospective studies testing the hypothesis that anxiety symptoms and diagnoses precede telomere 
shortening showed inconsistent  findings20–23,55. Therefore, these inconsistent results and the lack of longitudinal 
studies reveal that there is a gap to be filled concerning TL and  anxiety56. This is especially true if we considered 
young individuals.
Despite methodological limitations in telomere shortening studies, novel and more specific aging markers, 
such as an integrative analysis involving multiple biomarkers are needed. Thus, epigenetic aging can be used as 
an index of disproportionate or accelerated biological cell  aging57. In our study, we found no significant differ-
ences in AA between anxiety disorder groups and controls in GLMM analysis. Wolf et al.29 examined if different 
psychiatric disorders, including generalized anxiety disorders (GAD), predicted acceleration of DNA methylation 
age over time, and failed to demonstrate any significant associations between this marker and GAD. Moreover, 
Fries et al.26 reported statistically differences in AA between bipolar patients and healthy controls only in a sub-
sample of patients with more than 33-year-old. This data, in agreement with our study, suggested that epigenetic 
aging could not be a valuable marker of cellular aging or neural development in young individuals.
Furthermore, we were not able to demonstrate any correlations between TL and AA. Other studies investigat-
ing the correlation between these markers had also shown some contradictory results. Shorter TL was associated 
with increased extrinsic AA in postmenopausal  women15, but telomere length did not significantly correlate with 
epigenetic accelerated aging in a study including bipolar disorder patients, their siblings, and healthy  controls26. 
Although a mismatch can occur between DNAm age and chronological  age57, studies suggested that AA and TL 
are uncorrelated. Both processes predict chronological age independently because epigenetic aging and cellular 
senescence are independent mechanisms that do not need to occur  together58,59. Moreover, we were able to dem-
onstrate correlation of chronological age with TL and DNAm age, but not with AA. Consistently, the correlation 
between Horvath DNAm age (predicted age) and chronological age is well  described27,30,57,60. Nevertheless, since 
AA is all epigenetic age that is not explained by the chronological age, characterizing the acceleration, this vari-
able does not necessarily correlate with chronological age, as shown in previous  studies30,61.
Some limitations of the present study were the small sample size and the ethnic background of our popula-
tion. However, we try to minimize this confounder, adjusting our analyses to ethnicity. Our small sample size 
may be underpowered to show possible differences among the groups. We attempt to minimize this by using a 
mixed-effect model, which uses all information available from both time points. Furthermore, only 47 subjects 
were selected to undergo genome-wide DNA methylation and AA estimation, which, despite small, was rep-
resentative of the whole studied sample. Also, as we analyzed anxiety diagnoses as a group, we might have lost 
some specificity of the different anxiety disorders. Moreover, quantification of telomeres and DNA methylation 
analyses were derived from saliva samples which comprised heterogeneous cell types, however, several studies 
indicate that high-quality methylation profiles can be generated from  saliva62. DNA methylation from saliva 
seems to be more similar to the DNA methylation from brain cells as compared to methylation in a blood cell 
 sample63. Importantly, Horvath’s clock is a multi-tissue predictor of age that allows estimating the DNAm age 
and AA of most tissues and cell types, including  saliva57. Similarly, studies demonstrated that telomere lengths 
from different tissues are significantly  correlated64–66. Finally, some important factors associated with AA and/
or TL, such as perceived stress, childhood adversities, educational attainment, body weight, physical activity, 
sleep duration, smoking, sex hormones, inflammation, and oxidative  stress67–69 were not considered in this study.
On the other hand, our manuscript brings several new preliminary pieces of evidences about anxiety in 
childhood and adolescence. Our sample came from a middle income country that face different socioeconomic 
constraints, such as higher inequality, violence and precarious supportive network, important environmental 
factors associated with epigenetic factors. To our knowledge, no longitudinal studies were investigating epige-
netic aging in adolescents using an extensive evaluation and following a stringent criterion for anxiety disorders 
diagnoses. Moreover, our study evaluated the association between anxiety disorders and two different biological 
clocks, using different and uncorrelated methodological procedures (TL and AA).
Therefore, our findings suggest that adolescents with persistent anxiety did not change telomere length over 
time, which could be associated with a delay in neuronal development in this period of life. Present findings 
also encourage TL as a more sensitive biomarker for anxiety disorders rather than AA. Further longitudinal 
studies evaluating these and other biological clocks over time in adolescence will allow us to better understand 
the cellular aging and associations with neuronal development, as well as the search for the best biomarkers in 
anxiety disorders at this life stage.
Methods
Sample selection and psychiatric evaluation. This study was approved by the Ethics Committee of 
the Hospital de Clínicas de Porto Alegre (HCPA), Brazil (protocol number 15–0349), and all parents or individu-
als over 18 years signed an informed consent form before entering the study. All procedures were followed in 
accordance with relevant guidelines.
Two hundred thirty four (n = 234) non-medicated children and adolescents were recruited from public schools 
in 2008 and assessed with an extensive psychiatric evaluation, as previously described by Salum et al.3. After 
these evaluations, 134 individuals were diagnosed with anxiety disorders and 100 individuals were classified as 
non-anxious controls. These 234 subjects were invited to participate in the 5-year follow-up survey and a total of 
76 adolescents and young adults agreed to participate in this second phase of the study. They were re-evaluated 
using the Schedule for Affective Disorders and Schizophrenia for School-Age Children Present and Lifetime 
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Version (K-SADS-PL) if less than 18 year-old or the Mini International Neuropsychiatric Interview (MINI)70 if 
19 years of age or older. Saliva samples were collected in both evaluations to extract DNA.
We categorized the 76 participants that were evaluated twice into three groups according to their diagnostic 
status at both evaluations: (1) control group (no anxiety disorder at both time points, n = 18), (2) variable group 
(presence of any anxiety disorder in only one time point, n = 38) and (3) persistent group (anxiety disorder at 
both time points, n = 20). We further decomposed the variable group into incident (n = 16) and remittent groups 
(n = 22) and replicated all analysis considering these groups (see “Supplementary information”).
DNA extraction. DNA was extracted from biological samples of saliva, collected at baseline (2008) and the 
end-point of follow-up (2013), using an Oragene Kit (DNA Genotek, Ottawa, Ontario, Canada). We checked 
nucleic acid concentration and purity spectrophotometrically (BioPhotometer Plus, Eppendorf, Hamburg, Ger-
many) and all samples were stored at − 20 °C until subsequent analysis.
Measurement of relative telomere length (T/S). We used genomic DNA (25 ng/reaction) as template 
for quantification of relative mean TL (T/S) by real time quantitative polymerase chain reaction (qPCR)71, with 
minor  modifications60. We performed two separate qPCR in the same position for each sample; one reaction 
amplified the telomere (T) repeated sequence while the other amplified a single copy gene, 36B4 (S), as a quan-
titative control. All reactions were performed in triplicate in separate 96-well plates. Relative TL was expressed 
as the T/S ratio for each participant. Primer  sequences71 were (5′ → 3′): tel1, GGT TTT TGA GGG TGA GGG TGA 
GGG TGA GGG TGA GGG T; tel2, TCC CGA CTA TCC CTA TCC CTA TCC CTA TCC CTA TCC CTA and 36B4u, 
CAG CAA GTG GGA AGG TGT AATCC and 36B4d, CCC ATT CTA TCA TCA ACG GGT ACA A. T and S master 
mix reactions followed the same concentrations with 0.1 × SYBR Green (Molecular Probes, CA, USA), 2 mM 
 MgCl2, 0.1 mM each dNTP, 1% DMSO and 0.5 U of Platinum Taq DNA Polymerase (Invitrogen). Final primer 
concentrations for telomere amplification were 270 and 1,125  nM for 1 e 2 telomeres primers, respectively; 
and 300 and 500 nM for 36B4u and 36B4d primers, respectively. We performed PCR reactions in StepOnePlus 
Real-time PCR system (Applied Biosystems, CA, USA) and analyzed with StepOne Software v2.3 (Applied Bio-
systems). Amplification consisted of an initial incubation step for 2 min at 94 °C to activate hot start Platinum 
Taq DNA polymerase, followed by 22 cycles of denaturing at 94 °C for 15 s and annealing and extension for 
2 min at 54 °C, for telomere amplification; and 30 cycles of denaturing at 94 °C for 15 s followed by annealing 
and extension for 2 min at 60 °C for 36B4 amplification. We confirmed the specificity of the amplification at the 
end of each run using melting curve analyses. Additionally, PCR products were confirmed using agarose gel 
electrophoresis. A reference sample was included in each run, as a calibrator to normalize the participants’ T/S 
ratio and calculate the final T/S ratio. At last, we generated standard curves for telomere and 36B4 amplification 
from the reference sample, over a fivefold range by serial dilution from 100 to 0.16 ng of gDNA to check for PCR 
amplification efficiency. Inter-plate variability was 2.7%.
Array‑based genome‑wide DNA methylation assays. We extracted the genomic DNA (500 ng) from 
the saliva of the whole sample, however only 47 subjects paired by age, sex and different anxiety disorder tra-
jectories due to logistical and financial limitations were included in the methylation analysis. The samples were 
treated with sodium bisulphite using the EZ-96 DNA Methylation-Gold Kit (Zymo Research, Orange, CA, USA) 
according to the manufacturer’s protocol. DNA methylation status was performed using the Infinium Human-
Methylation450 (IHM450)  BeadChip72 which covers 99% of Ref Seq genes regions and 96% of CpG islands/CpG 
island regions to explore the genome-wide DNA  methylome72–74. Data regarding pre-processing of raw data of 
IHM450 BeadChip and differential methylation analysis can be found  elsewhere39. All data of DNA methylation 
including methylated vs. unmethylated probes are deposited in GEO (GSE78975).
Epigenetic age acceleration (AA). DNA methylation age (DNAm age) and epigenetic age acceleration 
(AA) were calculated in samples using the Horvath age estimation  algorithm57, which is a multi-tissue (includ-
ing saliva) predictor of age that predicts DNAm age based on the methylation levels of 353 CpGs from the 
IHM450 BeadChip. As input to the age estimation algorithm, non-processed methylation data was used, as rec-
ommended by Horvath (https:// horva th. genet ics. ucla. edu/ html/ dnama ge/ faq. htm#_ Toc38 51474 15). This tool 
algorithm free available online (http:// labs. genet ics. ucla. edu/ horva th/ htdocs/ dnama ge/)57 provides an estimate 
of DNAm age and predicts AA (in years) using elastic net-penalized regression models (in R package) of DNAm 
age on chronological age. Regression models result in residuals that were compared among groups. Therefore, 
AA was defined as the residuals from regressing DNAm age on actual (chronological) age.
Statistical analysis. Sample characteristics were described as median (minimum and maximum), means 
(standard deviations) or percentages. Chi-squared test was applied for testing sex and race/ethnicity between 
anxiety groups. We used analysis of variance (ANOVA) and Tukey post-hoc tests to examine TL, AA and chron-
ological age differences among anxiety groups within each year. Furthermore, we used T test to examine mean 
differences in TL and AA for each anxiety group and for the overall sample between the two assessments.
We investigated the correlation between TL and AA, and correlations of TL, AA or DNAm age and chronolog-
ical age using Spearman correlations due to the positive-skewness nature of these variables. We used generalized 
linear mixed models (GLMM) with random effects and adding interaction term with time, applying penalized 
quasi-likelihood parameter estimator to better fit non-normal distributed  data75. This was calculated to examine 
if the anxiety groups are associated with the levels of TL or AA and their changes over time. We modeled TL and 
AA as dependent variables, time and anxiety disorder groups as fixed factors and subjects as random variable 
(random intercepts). To control for potential confounders, we adjusted the analysis for age, sex and ethnicity.
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All statistical analyses were performed using SPSS v. 23.0 (SPSS Inc., Chicago, IL, USA) and in R, using the 
MASS package in R and the glmPQL  function76. Significance levels were set to be p < 0.05.
Ethics approval. This study was approved by the Ethics Committee of the Hospital de Clínicas de Porto 
Alegre (HCPA), Brazil (protocol number 15-0349). All procedures were followed in accordance with relevant 
guidelines.
Consent to participate. All parents or individuals over 18 years signed an informed consent form before 
entering the study.
Data availability
All data of DNA methylation including methylated vs. unmethylated probes are deposited in GEO (GSE78975).
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